Cornerstone, Medimmune Split
Cary-based specialty pharmaceutical company Cornerstone Therapeutics and Maryland's MedImmune have ended a drug-development relationship targeting new treatments for inflammation.
The firms said they mutually ended the 7-year-old agreement, but gave no reason.
The firms were developing a protein technology Cornerstone originally licensed from New York's Feinstein Institute for Medical Research to treat inflammations related to conditions such as stroke, heart attack and arthritis.
Cornerstone said it has acquired all rights to the technology and plans to seek another partner in its development.